IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
IgniteData has partnered with AstraZeneca (AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to implement its Archer platform in an ongoing Phase 3 study. The platform automates data transfer between hospital Electronic Health Records and sponsor Electronic Data Capture systems.
The collaboration, which began in 2021, follows successful pilot studies at University College London Hospitals and Memorial Sloan Kettering Cancer Center. Archer's system-agnostic design can map hundreds of data points per patient while maintaining data security and privacy.
The platform aims to reduce time spent on manual data entry, allowing researchers to focus more on clinical research. This implementation at Cambridge marks a significant step in scaling the technology across NHS and European hospitals for future clinical trials.
IgniteData ha stretto una partnership con AstraZeneca (AZN) e Cambridge University Hospitals NHS Foundation Trust (CUH) per implementare la sua piattaforma Archer in uno studio di Fase 3 in corso. La piattaforma automatizza il trasferimento dei dati tra i registri elettronici di salute degli ospedali e i sistemi di cattura elettronica dei dati degli sponsor.
La collaborazione, iniziata nel 2021, segue studi pilota di successo presso gli ospedali dell'University College London e il Memorial Sloan Kettering Cancer Center. Il design della piattaforma Archer, indipendente dai sistemi, può mappare centinaia di punti dati per paziente, mantenendo al contempo la sicurezza e la privacy dei dati.
La piattaforma mira a ridurre il tempo dedicato all'inserimento manuale dei dati, consentendo ai ricercatori di concentrarsi maggiormente sulla ricerca clinica. Questa implementazione a Cambridge segna un passo significativo nella scalabilità della tecnologia negli ospedali del NHS e in quelli europei per futuri studi clinici.
IgniteData se ha asociado con AstraZeneca (AZN) y Cambridge University Hospitals NHS Foundation Trust (CUH) para implementar su plataforma Archer en un estudio de Fase 3 en curso. La plataforma automatiza la transferencia de datos entre los Registros Electrónicos de Salud del hospital y los sistemas de Captura Electrónica de Datos del patrocinador.
La colaboración, que comenzó en 2021, sigue a estudios piloto exitosos en los hospitales de University College London y el Memorial Sloan Kettering Cancer Center. El diseño agnóstico del sistema de Archer puede mapear cientos de puntos de datos por paciente, manteniendo la seguridad y la privacidad de los datos.
La plataforma tiene como objetivo reducir el tiempo dedicado a la entrada manual de datos, permitiendo a los investigadores concentrarse más en la investigación clínica. Esta implementación en Cambridge marca un paso significativo en la escalabilidad de la tecnología en los hospitales del NHS y europeos para futuros ensayos clínicos.
IgniteData는 AstraZeneca (AZN) 및 Cambridge University Hospitals NHS Foundation Trust (CUH)와 협력하여 진행 중인 3상 연구에서 Archer 플랫폼을 구현하고 있습니다. 이 플랫폼은 병원 전자 건강 기록과 스폰서 전자 데이터 캡처 시스템 간의 데이터 전송을 자동화합니다.
2021년에 시작된 이 협력은 University College London Hospitals와 Memorial Sloan Kettering Cancer Center에서 성공적인 파일럿 연구를 따릅니다. Archer의 시스템 비종속적 설계는 환자당 수백 개의 데이터 포인트를 매핑할 수 있으며, 데이터 보안과 개인 정보를 유지합니다.
이 플랫폼은 수동 데이터 입력에 소요되는 시간을 줄여 연구자들이 임상 연구에 더 집중할 수 있도록 하는 것을 목표로 합니다. 케임브리지에서의 이 구현은 NHS 및 유럽 병원에서 미래의 임상 시험을 위한 기술 확장의 중요한 단계를 의미합니다.
IgniteData s'est associé à AstraZeneca (AZN) et à Cambridge University Hospitals NHS Foundation Trust (CUH) pour mettre en œuvre sa plateforme Archer dans le cadre d'une étude de Phase 3 en cours. La plateforme automatise le transfert de données entre les dossiers de santé électroniques des hôpitaux et les systèmes de capture électronique de données des sponsors.
La collaboration, qui a débuté en 2021, fait suite à des études pilotes réussies à l'University College London Hospitals et au Memorial Sloan Kettering Cancer Center. La conception agnostique du système Archer peut cartographier des centaines de points de données par patient tout en maintenant la sécurité et la confidentialité des données.
La plateforme vise à réduire le temps consacré à la saisie manuelle des données, permettant ainsi aux chercheurs de se concentrer davantage sur la recherche clinique. Cette mise en œuvre à Cambridge représente une étape significative dans l'extension de la technologie dans les hôpitaux du NHS et européens pour de futurs essais cliniques.
IgniteData hat sich mit AstraZeneca (AZN) und Cambridge University Hospitals NHS Foundation Trust (CUH) zusammengetan, um seine Archer-Plattform in einer laufenden Phase-3-Studie zu implementieren. Die Plattform automatisiert den Datentransfer zwischen den elektronischen Gesundheitsakten des Krankenhauses und den elektronischen Datenerfassungssystemen der Sponsoren.
Die Zusammenarbeit, die 2021 begann, folgt erfolgreichen Pilotstudien an den University College London Hospitals und dem Memorial Sloan Kettering Cancer Center. Das systemunabhängige Design von Archer kann Hunderte von Datenpunkten pro Patient abbilden und dabei die Datensicherheit und Privatsphäre wahren.
Die Plattform zielt darauf ab, die Zeit für manuelle Dateneingabe zu reduzieren, damit sich die Forscher stärker auf die klinische Forschung konzentrieren können. Diese Implementierung in Cambridge markiert einen bedeutenden Schritt zur Skalierung der Technologie in NHS- und europäischen Krankenhäusern für zukünftige klinische Studien.
- Implementation of automated data transfer system could reduce operational costs and improve efficiency in AZN's clinical trials
- Successful pilot studies at major medical centers demonstrate platform's viability
- Potential for global scaling across hospitals could accelerate clinical trial processes
- Initial implementation to single Phase 3 study
- Return on investment and actual cost savings not yet quantified
Insights
This collaboration between AstraZeneca, Cambridge University Hospitals, and IgniteData represents an important step forward in clinical trial efficiency. The Archer platform addresses one of the most persistent challenges in clinical research: the labor-intensive process of transferring patient data from hospital systems to clinical trial databases.
The deployment in an ongoing Phase 3 study is particularly noteworthy, as late-stage trials involve extensive data collection and monitoring. By automating the transfer of several hundred data points per patient, this technology could significantly reduce workload for research staff while improving data accuracy by eliminating manual transcription errors.
What distinguishes this implementation is its system-agnostic design, enabling integration with various electronic health records and data capture systems. The successful pilots at prestigious institutions like Memorial Sloan Kettering Cancer Center validate the platform's functionality in complex research environments.
For AstraZeneca, this represents an incremental operational improvement rather than a transformative clinical advancement. However, these efficiency gains, when scaled across multiple trials and sites, could accumulate into meaningful time and resource savings across their research portfolio. The planned expansion to other European hospitals indicates confidence in the platform's value proposition.
AstraZeneca's strategic investment in clinical trial infrastructure through this collaboration demonstrates forward thinking in research operations. While not generating immediate revenue, these digital transformation initiatives address significant pain points in the pharmaceutical development process.
The multi-year commitment since 2021 indicates this isn't a one-off project but rather part of a sustained digital strategy. By participating in the platform's development, AstraZeneca may have shaped it to address specific operational challenges they've encountered across their extensive clinical program.
What's particularly valuable is the focus on data integrity alongside efficiency. Regulatory submissions depend on pristine clinical data, and automated transfers may reduce documentation errors that could otherwise delay approvals. The system's ability to maintain patient privacy while transferring substantial data volumes addresses critical compliance requirements.
The economic impact remains unquantified - the article provides no metrics on time savings, error reduction rates, or cost efficiencies. However, considering that Phase 3 trials typically cost
This development aligns with the broader industry shift toward digitizing clinical research operations but represents an evolutionary rather than revolutionary advancement for AstraZeneca's research capabilities.
IgniteData's Archer tool is a technology platform that upholds the highest standards of data security and automates the data transfer process between hospital Electronic Health Records (EHRs) and sponsor Electronic Data Capture (EDCs), allowing researchers to focus more of their time on clinical research and less time on data entry. With its system-agnostic design, Archer integrates effortlessly with leading EHRs and EDCs to map a multitude of study variables and transfer several hundred data points per patient, resulting in significant time savings while ensuring the highest levels of data integrity and maintaining patient data privacy.
The collaboration between Cambridge University Hospitals, AstraZeneca, and IgniteData began in 2021, with AstraZeneca playing a key role in developing the Archer platform. After successful pilot studies at University College London Hospitals (UCLH) and Memorial Sloan Kettering Cancer Center (MSK), Archer is now being deployed in this pivotal study at
Richard Yeatman, COO of IgniteData, added, "Our partnership with Cambridge University Hospitals and AstraZeneca is a testament to the power of collaboration in advancing clinical research. With Archer, we are laying the groundwork for a new era of digital innovation in clinical trials, one where data is transferred seamlessly, securely, and efficiently."
Looking Ahead
The data and insights gained from this live integration will inform future deployments of Archer across other NHS and European hospitals. This marks just the beginning of a broader initiative to scale this technology globally with approved sponsors, transforming the way clinical trials are conducted and accelerating the delivery of life-saving treatments to patients.
For more information about Archer and its role in modern clinical trials, visit IgniteData's website.
About IgniteData
IgniteData is the company shaping the future of clinical trials. Through its innovative digihealth platform, Archer, it is enhancing interoperability between Electronic Health Records (EHR) and key research applications such as Electronic Data Capture (EDC).
IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research systems, such as EDC, to provide seamless, secure transfer of clinically- validated data for clinical trials.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ignitedata-launches-cutting-edge-data-integration-platform-for-clinical-trials-at-cambridge-university-hospitals-302403035.html
SOURCE IgniteData
FAQ
What is the purpose of IgniteData's Archer platform in AstraZeneca's Phase 3 trial?
Where has AstraZeneca's Archer platform been successfully piloted before the Cambridge implementation?
When did the collaboration between IgniteData and AstraZeneca begin?
How many data points can the Archer platform transfer per patient in AZN's clinical trials?
